SCHEMBL5480076

SCHEMBL5480076

CC(=O)Oc1ccc(C2(c3ccc(OC(C)=O)cc3)C(=S)Nc3c2ccc(Cl)c3C)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.43
LMNA P02545 3/20 0.39
POLB P06746 1/20 0.33
PKM P14618 1/20 0.33
ELANE P08246 1/20 0.33
HSD17B10 Q99714 1/20 0.32
GAA P10253 2/20 0.31
ALDH1A1 P00352 1/20 0.31
HSP90AA1 P07900 1/20 0.31
CES1 P23141 1/20 0.31
KMT2A Q03164 2/20 0.31
KDM4E B2RXH2 2/20 0.31
SMN1; SMN2 Q16637 2/20 0.31
MEN1 O00255 1/20 0.31
TTR P02766 1/20 0.31
TP53 P04637 1/20 0.31
CYP3A4 P08684 1/20 0.31
GLA P06280 2/20 0.30
ACHE P22303 1/20 0.30
KIF11 P52732 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5482053 0.86 MAPT (0.56) MAPTLMNAPOLBPKMELANE
SCHEMBL5482277 0.81 SMN1; SMN2 (0.43) MAPTLMNAPOLBGAAALDH1A1
SCHEMBL5479391 0.81 CES1 (0.34) CES1
SCHEMBL5477636 0.80 CNR1 (0.40) PKMCES1
SCHEMBL5482232 0.78 MAPT (0.33) MAPTLMNAPOLBALDH1A1CES1
SCHEMBL5488975 0.76 MAPT (0.43) MAPTLMNAPOLBPKMELANE
SCHEMBL5483443 0.73 MAPT (0.43) MAPTLMNAPOLBPKMELANE
SCHEMBL5475119 0.71 MAPT (0.42) MAPTLMNAPOLBPKMELANE
SCHEMBL5481638 0.71 MAPT (0.40) MAPTLMNAPOLBHSD17B10ALDH1A1
SCHEMBL5479020 0.70 MAPT (0.48) MAPTLMNAPOLBPKMELANE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer TOPO TARGET A/S (DK) 2007-12-27 US claimed
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer TOPO TARGET A/S (DK) 2007-12-27 US disclosed
EP-1734951-A2 DIPHENYL-INDOL-2-ON COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER TopoTarget A/S (DK) 2006-12-27 EP disclosed
WO-2005097107-A2 DIPHENYL - INDOL-2-ON COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER TOPOTARGET A/S (DK) 2005-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer MTOR, RICTOR, CDK4 MAPT 1785/4885LMNA 3104/4885POLB 4297/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.